CVS Health Recognized for Technology That Improves Medication Safety and Patient Care
NORTHAMPTON, MA AND WOONSOCKET, RI / ACCESS Newswire / June 9, 2026 / CVS HealthThe company was awarded a 2026...
Pharmaceutical
Ignite Biomedical and Liquid Biosciences Partner to Discover First-in-Class Drug Targets
No approved drug, clinical-stage asset, or competing research program targets the mechanisms that Liquid's Emerge platform identifies. FRAMINGHAM, MA /...
UniDoc Connect Surpasses One Million Patient Visits
Company Records 250,000 Patient Visits in First Six Months Since AMD Purchase, Then Triples to 750,000 in the Following Six...
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response...
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market U.S. naloxone...
Linnaeus Therapeutics Announces Selection of LNS8801 into the National Institute on Aging Interventions Testing Program
Selection by both the NIA ITP and ARPA-H PROSPR programs highlights growing recognition of LNS8801’s potential to promote healthy agingHADDONFIELD,...
Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium in sepsis
Product rendering Isupartob sodium - 3 vials Geleen, June 9, 2026 Matisse Pharmaceuticals B.V., a clinical stage company developing a...
Chiesi Global Rare Diseases Announces Health Canada Grants Priority Review for FILSUVEZ® (birch triterpenes) Topical Gel for the Treatment of Epidermolysis Bullosa
Priority review recognizes the serious nature of epidermolysis bullosa (EB) and the urgent need for continued evaluation of potential treatment...
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to...
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK...
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis...
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore...
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth
Alison Strutt appointed as Chief Financial Officer, László Tankó appointed as Consultant Chief Medical Officer, and Sam Fazeli appointed Non-Executive...
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors Copenhagen, Denmark, 09 June 2026 – Antag Therapeutics...
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies...
NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026
TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
BPGbio Appoints Renowned Neuroscientist Eric J. Nestler, M.D., Ph.D., as Chair of Scientific Advisory Board
BPGbio Appoints Renowned Neuroscientist Eric J. Nestler, M.D., Ph.D., as Chair of Scientific Advisory Board Dr. Nestler, world-renowned neuroscientist, Dean...
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09,...
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
The new independent directors strengthen the Company’s board as seasoned executives bring deep expertise in life sciences commercialization, healthcare administration,...
Apollo Therapeutics Appoints Timothy P. Walbert as Chairman of the Board
Mr. Walbert brings more than 30 years of biopharmaceutical leadership, including founding and leading Horizon Therapeutics through to its approximately...